Immucell Corporation (ICCC) fundamentals score
ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves.
In Vitro & In Vivo Diagnostic Substances · Healthcare · Listed on NASDAQ
Overall: 7.0 out of 10, Good long-term fundamentals
- Growth: 5.1/10
- Profitability: 7.5/10
- Financial health: 9.4/10
- Earnings quality: 9.4/10
- Valuation: 4.0/10
Scores are calculated from Immucell Corporation’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10